ES2349213T3 - Ligandos de ácido nucleico inhibidores de las adn polimerasas. - Google Patents
Ligandos de ácido nucleico inhibidores de las adn polimerasas. Download PDFInfo
- Publication number
- ES2349213T3 ES2349213T3 ES00914690T ES00914690T ES2349213T3 ES 2349213 T3 ES2349213 T3 ES 2349213T3 ES 00914690 T ES00914690 T ES 00914690T ES 00914690 T ES00914690 T ES 00914690T ES 2349213 T3 ES2349213 T3 ES 2349213T3
- Authority
- ES
- Spain
- Prior art keywords
- baselineskip
- seq
- polymerase
- dna
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 400
- 150000007523 nucleic acids Chemical class 0.000 title claims description 184
- 102000039446 nucleic acids Human genes 0.000 title claims description 178
- 108020004707 nucleic acids Proteins 0.000 title claims description 178
- 239000003112 inhibitor Substances 0.000 title claims description 63
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 title claims description 61
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 title claims description 61
- 238000000034 method Methods 0.000 claims abstract description 92
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 18
- 238000003752 polymerase chain reaction Methods 0.000 claims description 128
- 238000009739 binding Methods 0.000 claims description 87
- 230000027455 binding Effects 0.000 claims description 85
- 125000003729 nucleotide group Chemical group 0.000 claims description 85
- 239000002773 nucleotide Substances 0.000 claims description 80
- 238000006243 chemical reaction Methods 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 44
- 108020004414 DNA Proteins 0.000 claims description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 17
- 238000003786 synthesis reaction Methods 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- 230000006820 DNA synthesis Effects 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 3
- 238000005382 thermal cycling Methods 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 2
- 238000009004 PCR Kit Methods 0.000 claims 1
- 238000001668 nucleic acid synthesis Methods 0.000 claims 1
- 108010006785 Taq Polymerase Proteins 0.000 abstract description 180
- 108010020713 Tth polymerase Proteins 0.000 abstract description 99
- 108091034117 Oligonucleotide Proteins 0.000 abstract description 40
- 230000000694 effects Effects 0.000 description 133
- 239000000047 product Substances 0.000 description 83
- 230000005764 inhibitory process Effects 0.000 description 75
- 230000003321 amplification Effects 0.000 description 52
- 238000003199 nucleic acid amplification method Methods 0.000 description 52
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 38
- 238000011534 incubation Methods 0.000 description 35
- 108060002716 Exonuclease Proteins 0.000 description 34
- 239000000872 buffer Substances 0.000 description 34
- 102000013165 exonuclease Human genes 0.000 description 34
- 239000012634 fragment Substances 0.000 description 30
- 239000000758 substrate Substances 0.000 description 26
- 102000004190 Enzymes Human genes 0.000 description 25
- 108090000790 Enzymes Proteins 0.000 description 25
- 239000011541 reaction mixture Substances 0.000 description 25
- 102100034343 Integrase Human genes 0.000 description 24
- 238000003776 cleavage reaction Methods 0.000 description 24
- 230000007017 scission Effects 0.000 description 24
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 22
- 230000006870 function Effects 0.000 description 22
- 239000000499 gel Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 20
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 19
- 238000003314 affinity selection Methods 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 19
- 239000012148 binding buffer Substances 0.000 description 19
- 239000000020 Nitrocellulose Substances 0.000 description 18
- 238000003556 assay Methods 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 229920001220 nitrocellulos Polymers 0.000 description 18
- 239000011324 bead Substances 0.000 description 17
- 239000000539 dimer Substances 0.000 description 17
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 16
- 102000053602 DNA Human genes 0.000 description 16
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 15
- 230000003993 interaction Effects 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 108091023037 Aptamer Proteins 0.000 description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 13
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 108020004682 Single-Stranded DNA Proteins 0.000 description 12
- 229920002401 polyacrylamide Polymers 0.000 description 12
- 230000009897 systematic effect Effects 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 239000000178 monomer Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 208000031886 HIV Infections Diseases 0.000 description 9
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
- 102000008100 Human Serum Albumin Human genes 0.000 description 8
- 108091006905 Human Serum Albumin Proteins 0.000 description 8
- 239000007997 Tricine buffer Substances 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108091093088 Amplicon Proteins 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 241000713869 Moloney murine leukemia virus Species 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000710 homodimer Substances 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 239000011574 phosphorus Substances 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 108700042226 ras Genes Proteins 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 108010068698 spleen exonuclease Proteins 0.000 description 6
- 241000589596 Thermus Species 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 231100000219 mutagenic Toxicity 0.000 description 5
- 230000003505 mutagenic effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 108091035707 Consensus sequence Proteins 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 101150040459 RAS gene Proteins 0.000 description 4
- 108010001244 Tli polymerase Proteins 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 239000000833 heterodimer Substances 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- -1 iodoacetyl Chemical group 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 229940113082 thymine Drugs 0.000 description 4
- PSOZMUMWCXLRKX-UHFFFAOYSA-N 2,4-dinitro-6-pentan-2-ylphenol Chemical compound CCCC(C)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O PSOZMUMWCXLRKX-UHFFFAOYSA-N 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 241000557720 Thermus brockianus Species 0.000 description 3
- 241000589499 Thermus thermophilus Species 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000000376 autoradiography Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 102100022385 Activity-dependent neuroprotector homeobox protein Human genes 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101000755474 Homo sapiens Activity-dependent neuroprotector homeobox protein Proteins 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229940123066 Polymerase inhibitor Drugs 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000205180 Thermococcus litoralis Species 0.000 description 2
- 241000204666 Thermotoga maritima Species 0.000 description 2
- 241000589500 Thermus aquaticus Species 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 2
- 239000011049 pearl Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- RGNOTKMIMZMNRX-XVFCMESISA-N 2-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-4-one Chemical group NC1=NC(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RGNOTKMIMZMNRX-XVFCMESISA-N 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 1
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 1
- KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000713838 Avian myeloblastosis virus Species 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229940127399 DNA Polymerase Inhibitors Drugs 0.000 description 1
- 241000052343 Dares Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 238000003705 background correction Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical group OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007850 in situ PCR Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 102000044158 nucleic acid binding protein Human genes 0.000 description 1
- 108700020942 nucleic acid binding protein Proteins 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 150000008163 sugars Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008542 thermal sensitivity Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US258797 | 1988-10-17 | ||
| US09/258,797 US6183967B1 (en) | 1995-06-07 | 1999-03-01 | Nucleic acid ligand inhibitors to DNA polymerases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2349213T3 true ES2349213T3 (es) | 2010-12-29 |
Family
ID=22982164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00914690T Expired - Lifetime ES2349213T3 (es) | 1999-03-01 | 2000-02-24 | Ligandos de ácido nucleico inhibidores de las adn polimerasas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6183967B1 (de) |
| EP (2) | EP1171632B1 (de) |
| JP (2) | JP4738599B2 (de) |
| AT (1) | ATE478157T1 (de) |
| AU (1) | AU781567B2 (de) |
| CA (1) | CA2362526A1 (de) |
| DE (1) | DE60044845D1 (de) |
| DK (1) | DK1171632T3 (de) |
| ES (1) | ES2349213T3 (de) |
| HK (1) | HK1044803B (de) |
| PT (1) | PT1171632E (de) |
| WO (1) | WO2000052207A1 (de) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6830902B1 (en) * | 1999-07-02 | 2004-12-14 | Invitrogen Corporation | Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis |
| US7312325B2 (en) * | 2000-09-26 | 2007-12-25 | Duke University | RNA aptamers and methods for identifying the same |
| DK2070939T3 (da) * | 2001-05-25 | 2014-06-23 | Univ Duke | Modulatorer af farmakologiske midler |
| US6667165B2 (en) | 2001-11-13 | 2003-12-23 | Eppendorf Ag | Method and compositions for reversible inhibition of thermostable polymerases |
| EP1594982A4 (de) * | 2003-01-29 | 2006-04-12 | Quanta Biosciences Inc | Verfahren und zusammensetzungen zum nachweis und zur quantifizierung von rna |
| AU2004227353B2 (en) | 2003-04-01 | 2010-02-25 | Luminex Corporation | Polymerase inhibitor and method of using same |
| US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| EP2460811A1 (de) * | 2004-04-22 | 2012-06-06 | Regado Biosciences, Inc. | Verbesserte Modulatoren von Gerinnungsfaktoren |
| WO2005123913A2 (en) * | 2004-06-09 | 2005-12-29 | Nustar Laboratory | Reversibly modified thermostable enzyme compositions and methods of making and using the same |
| US20060019288A1 (en) * | 2004-06-30 | 2006-01-26 | Applera Corporation | Methods, reaction mixtures, and kits for ligating polynucleotides |
| ATE541055T1 (de) * | 2004-10-18 | 2012-01-15 | Univ Brandeis | Reagenzien und verfahren zur verbesserung der reproduzierbarkeit und zur reduzierung des mispriming bei der pcr-amplifikation |
| US20060228726A1 (en) * | 2005-01-06 | 2006-10-12 | Martin Patrick K | Polypeptides having nucleic acid binding activity and compositions and methods for nucleic acid amplification |
| US20070059713A1 (en) * | 2005-09-09 | 2007-03-15 | Lee Jun E | SSB-DNA polymerase fusion proteins |
| US20070212704A1 (en) | 2005-10-03 | 2007-09-13 | Applera Corporation | Compositions, methods, and kits for amplifying nucleic acids |
| WO2007092538A2 (en) * | 2006-02-07 | 2007-08-16 | President And Fellows Of Harvard College | Methods for making nucleotide probes for sequencing and synthesis |
| CN106566855B (zh) * | 2006-07-31 | 2021-11-09 | 苏州新海生物科技股份有限公司 | 使用可逆修饰寡核苷酸扩增核酸 |
| US9045522B2 (en) | 2006-07-31 | 2015-06-02 | Wanli Bi | Nucleic acid amplification using a reversibly modified oligonucleotide |
| CN101802225B (zh) | 2007-07-17 | 2013-10-30 | 私募蛋白质体公司 | 检测样品的多元分析 |
| GB0806562D0 (en) | 2008-04-10 | 2008-05-14 | Fermentas Uab | Production of nucleic acid |
| EP2113574A1 (de) | 2008-04-28 | 2009-11-04 | Biotype AG | Stoffe und Verfahren für Profilierungstest auf DNA-Basis |
| US8841429B2 (en) * | 2009-11-03 | 2014-09-23 | Vivonics, Inc. | Nucleic acid ligands against infectious prions |
| US8236570B2 (en) * | 2009-11-03 | 2012-08-07 | Infoscitex | Methods for identifying nucleic acid ligands |
| KR20130138700A (ko) * | 2012-06-11 | 2013-12-19 | 삼성테크윈 주식회사 | 절단가능한 올리고뉴클레오티드 저해제에 의한 ｄｎａ 폴리머라제의 제어된 저해 및 재활성화 |
| US11473140B2 (en) * | 2013-11-26 | 2022-10-18 | Lc Sciences Lc | Highly selective omega primer amplification of nucleic acid sequences |
| CN103966184A (zh) * | 2014-05-06 | 2014-08-06 | 江西省科学院微生物研究所 | 一种实时热启动Taq酶及其制备方法 |
| JP7106461B2 (ja) | 2016-06-07 | 2022-07-26 | セファイド | 熱安定性ポリメラーゼ阻害剤組成物及び方法 |
| CN107619430B (zh) * | 2017-10-17 | 2021-01-15 | 江西省科学院微生物研究所 | 一种热稳定的Taq酶温控亲和性配体及其制备方法、应用 |
| EP3818170A4 (de) * | 2018-07-02 | 2022-03-09 | Swift Biosciences, Inc. | Temperaturgesteuerte dna-polymeraseinhibitoren |
| CN112770776B (zh) | 2018-07-30 | 2025-08-19 | 瑞德库尔有限责任公司 | 用于样品处理或分析的方法和系统 |
| EP4097251A1 (de) | 2020-01-29 | 2022-12-07 | 10X Genomics, Inc. | Zusammensetzungen und verfahren zur analytdetektion |
| JP2023531027A (ja) * | 2020-06-22 | 2023-07-20 | ▲蘇▼州新海生物科技股▲ふん▼有限公司 | 核酸リガンド、およびその使用 |
| CA3189769A1 (en) * | 2020-07-29 | 2022-02-03 | Mgi Tech Co., Ltd. | Method for loading nucleic acid molecule on solid support |
| KR102661292B1 (ko) * | 2021-09-09 | 2024-04-30 | 포항공과대학교 산학협력단 | 금속 이온 반응성 dna 중합 효소 스위치 및 이에 의해 제어되는 등온 증폭 방법 |
| CN114214298A (zh) * | 2021-12-30 | 2022-03-22 | 苏州译酶生物科技有限公司 | 一种热启动Taq DNA聚合酶的制备方法 |
| CN115044588B (zh) * | 2022-06-16 | 2023-04-25 | 湖北省疾病预防控制中心（湖北省预防医学科学院） | 一种核酸适配体及热启动dna聚合酶 |
| CN115851889B (zh) * | 2022-11-30 | 2025-12-05 | 北京全式金生物技术股份有限公司 | 松三糖和可逆结合因子Oligo在提升荧光定量PCR全预混体系的保存稳定性中的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE229046T1 (de) | 1985-03-30 | 1987-12-17 | Marc Genf/Geneve Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
| WO1989006694A1 (en) | 1988-01-15 | 1989-07-27 | Trustees Of The University Of Pennsylvania | Process for selection of proteinaceous substances which mimic growth-inducing molecules |
| US5683867A (en) | 1990-06-11 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: blended SELEX |
| US5693502A (en) * | 1990-06-11 | 1997-12-02 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5874557A (en) * | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
| US5472841A (en) | 1990-06-11 | 1995-12-05 | Nexstar Pharmaceuticals, Inc. | Methods for identifying nucleic acid ligands of human neutrophil elastase |
| US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
| US5763173A (en) * | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand inhibitors to DNA polymerases |
| US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
| US5459015A (en) | 1990-06-11 | 1995-10-17 | Nexstar Pharmaceuticals, Inc. | High-affinity RNA ligands of basic fibroblast growth factor |
| US5527894A (en) | 1990-06-11 | 1996-06-18 | Nexstar Pharmacueticals, Inc. | Ligands of HIV-1 tat protein |
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
| US5543293A (en) | 1990-06-11 | 1996-08-06 | Nexstar Pharmaceuticals, Inc. | DNA ligands of thrombin |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5476766A (en) | 1990-06-11 | 1995-12-19 | Nexstar Pharmaceuticals, Inc. | Ligands of thrombin |
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| US5587468A (en) | 1990-06-11 | 1996-12-24 | University Research Corporation | High affinity nucleic acid ligands to HIV integrase |
| JPH06508022A (ja) | 1991-02-21 | 1994-09-14 | ギリアド サイエンシズ，インコーポレイテッド | 生体分子に特異的なアプタマーおよび生産方法 |
| US5338671A (en) | 1992-10-07 | 1994-08-16 | Eastman Kodak Company | DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody |
| US5567604A (en) | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
| US6020130A (en) * | 1995-06-07 | 2000-02-01 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands that bind to and inhibit DNA polymerases |
| US20170110787A1 (en) | 2015-10-14 | 2017-04-20 | Apple Inc. | Electronic Devices With Millimeter Wave Antennas And Metal Housings |
| US12393593B2 (en) | 2023-09-12 | 2025-08-19 | Optum, Inc. | Priority-driven federated query-based data caching |
-
1999
- 1999-03-01 US US09/258,797 patent/US6183967B1/en not_active Expired - Fee Related
-
2000
- 2000-02-24 HK HK02105273.5A patent/HK1044803B/en unknown
- 2000-02-24 DK DK00914690.3T patent/DK1171632T3/da active
- 2000-02-24 AU AU36047/00A patent/AU781567B2/en not_active Expired
- 2000-02-24 ES ES00914690T patent/ES2349213T3/es not_active Expired - Lifetime
- 2000-02-24 AT AT00914690T patent/ATE478157T1/de active
- 2000-02-24 WO PCT/US2000/004702 patent/WO2000052207A1/en not_active Ceased
- 2000-02-24 EP EP00914690A patent/EP1171632B1/de not_active Expired - Lifetime
- 2000-02-24 PT PT00914690T patent/PT1171632E/pt unknown
- 2000-02-24 JP JP2000602817A patent/JP4738599B2/ja not_active Expired - Lifetime
- 2000-02-24 CA CA002362526A patent/CA2362526A1/en not_active Abandoned
- 2000-02-24 EP EP10007279A patent/EP2241635A1/de not_active Withdrawn
- 2000-02-24 DE DE60044845T patent/DE60044845D1/de not_active Expired - Lifetime
-
2011
- 2011-01-13 JP JP2011004936A patent/JP2011103890A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011103890A (ja) | 2011-06-02 |
| ATE478157T1 (de) | 2010-09-15 |
| AU3604700A (en) | 2000-09-21 |
| EP2241635A1 (de) | 2010-10-20 |
| JP4738599B2 (ja) | 2011-08-03 |
| WO2000052207A9 (en) | 2001-10-25 |
| HK1044803B (en) | 2011-04-29 |
| EP1171632B1 (de) | 2010-08-18 |
| AU781567B2 (en) | 2005-06-02 |
| US6183967B1 (en) | 2001-02-06 |
| JP2002537825A (ja) | 2002-11-12 |
| CA2362526A1 (en) | 2000-09-08 |
| WO2000052207A1 (en) | 2000-09-08 |
| EP1171632A1 (de) | 2002-01-16 |
| HK1044803A1 (en) | 2002-11-01 |
| DE60044845D1 (de) | 2010-09-30 |
| DK1171632T3 (da) | 2010-11-08 |
| EP1171632A4 (de) | 2005-03-30 |
| PT1171632E (pt) | 2010-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2349213T3 (es) | Ligandos de ácido nucleico inhibidores de las adn polimerasas. | |
| ES2321243T3 (es) | Ligandos de acido nucleico que se unen a las adn polimerasas y las inhiben. | |
| US5763173A (en) | Nucleic acid ligand inhibitors to DNA polymerases | |
| US5693502A (en) | Nucleic acid ligand inhibitors to DNA polymerases | |
| Dang et al. | Oligonucleotide inhibitors ofTaqDNA polymerase facilitate detection of low copy number targets by PCR | |
| US5658738A (en) | Bi-directional oligonucleotides that bind thrombin | |
| US5874557A (en) | Nucleic acid ligand inhibitors to DNA polymerases | |
| US5786462A (en) | High affinity ssDNA ligands of HIV-1 reverse transcriptase | |
| ES2254306T3 (es) | Amplificacion usando cebadores modificados. | |
| Lin et al. | Inhibition of multiple thermostable DNA polymerases by a heterodimeric aptamer | |
| Burmeister et al. | 2-Deoxy purine, 2-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics | |
| RU2495046C2 (ru) | Реагент и способ предотвращения по меньшей мере одного ошибочного старта в амплификации полимеразной цепной реакции, наборы реагентов и олигонуклеотидов для осуществления амплификации посредством полимеразной цепной реакции | |
| Szyjka et al. | Observation of coordinated RNA folding events by systematic cotranscriptional RNA structure probing | |
| ES2656961T3 (es) | Uso de G-Clamp para mejorar la PCR específica de alelo | |
| ES2367469T3 (es) | Polianión para la amplificación mejorada de ácidos nucleicos. | |
| ES2358235T3 (es) | Ligandos de ácido nucleico que se unen a adn polimerasas y las inhiben. | |
| JP2005318884A (ja) | 核酸の増幅方法 | |
| JP2004531208A (ja) | 情報伝達アプタマーのｉｎｖｉｔｒｏ選択 |